The goals of this study were to understand the current market scenario for the treatment options of phenylketonuria (PKU) which includes food for medical purposes (FSMPs), and to assess the market’s growth potential through the end of 2025. This study explores market dynamics such as drivers, restraints, opportunities, and trends that impact the growth of the market. The main objective of the study is to present a comprehensive analysis of the current treatment market for phenylketonuria and the future directions of the market.

Reasons for Doing This Study
The phenylketonuria treatment market is currently growing, with a strong drug pipeline and upcoming treatment methods for the maintenance of this condition. Phenylketonuria is a genetic disorder which is inherited from the parents. It is a birth defect which results in the accumulation of amino acid phenylalanine due to low levels of the enzyme phenylalanine hydroxylase. It is a condition which demands life-long maintenance; there is no proper medication to treat it. This market has grown steadily since 2014, and the pipeline shows tremendous potential growth during the forecast period. Many major companies are working toward developing novel products and funding innovations and R&D. Market growth is also attributed to companies concentrating on strategic investments and acquisitions.